Julius Clinical are proud to announce the successful completion of recruitment for the PRImus-AD study, a clinical Phase II study which investigates the safety and efficacy of the drug candidate PRI-002 for the treatment of Alzheimer’s Disease.

On 25 February the 304th and final study participant was enrolled into study, ahead of schedule. This recruitment achievement was made possible through our strong collaboration with Priavoid, PRInnovation, and SPRIN-D, and we appreciate the trust they have placed in us to support this critical research.

We would like to send a message of thanks to the Principle Investigators and study teams at the 40 sites across 6 countries who have dedicated a huge amount of their time to ensuring the successful study set up and recruitment at their respective centres. We truly appreciate our close working relationship and your commitment to this study.

As the CRO for this important trial, Julius Clinical is honoured to contribute to advancing new treatments for Alzheimer’s Disease.

Read the full press release here.